Silymarin Loaded Novel Drug Delivery for Oral and Topical Administration
Silymarin is polyphenolic flavonoid obtained from the seeds of silybum marianum plant. It has various pharmacological properties such as hepatoprotective, anti-inflammatory, antioxidant, anti-carcinogenic, hypolipidemic properties. Silymarin has recently reported to be neuroprotective agent against neurodegenerative disease such as Alzheimer, Parkinson’s and cerebral ischemia. It contains eight active components, among which silibinin is the most active component. However, silymarin is BCS class II drug which having poor bioavailability due to extensive phase II metabolism, poor aqueous solubility, low permeability across intestinal epithelial cells and rapid excretion in bile and urine. Therefore, it is necessary to understand all formulations and analytical aspects including all possible future prospects. In this review a potential approach to enhance solubility, bioavailability and to develop a robust formulation is studied. The number of studies describes novel drug delivery system (NDDS) based formulations have been significantly increased. The raise in novel drug delivery exploitation is essentially due to defeated barriers within technological process of lipid based nanoparticles formulations and increased knowledge of underlying mechanisms of transport of NDDS via different route of administration. This review focuses on pharmacological properties of silymarin, challenges, benefits and application of novel drug delivery system. To reduce the adverse effects and toxicities novel drug delivery will be an attractive approach of current therapies.
Keywords: Silymarin, route of administration, novel drug delivery, bioavailability, solubility
2. Karkanis A, Bilalis D, Efthimiadou A, Cultivation of milk thistle ( Silybum marianum L . Gaertn.), a medicinal weed, Industrial Crops Products, 2011; 34(1):825–830.
3. Kim S, Choi MG, Lee HS, Lee SK, Kim SH, Kim WW, Silibinin Suppresses TNF-a-Induced MMP-9 Expression in Gastric Cancer Cells through Inhibition of the MAPK Pathway, Molecules, 2009; 14:4300–4311.
4. Morazzoni P, Montalbetti A, Malandrino S, Pifferi G, Comparative pharmacokinetics of silipide and silymarin in rats, European Journal of Drug Metabolism and Pharmacokinetics, 1993; 18(3):289–297.
5. Wu J, Lin L, Tsai T, Drug – drug interactions of silymarin on the perspective of pharmacokinetics, Journal of Ethnopharmacology, 2009; 121:185–193.
6. Janc P, Anzenbacherova E, Papous B, Lemr K, Luz P, Veinlichova A, Silybin Is Metabolized by Cytochrome P450 2C8 in Vitro, Drug Metabolism and Disposition, 2007; 35(11):2035–2039.
7. Wu J, Lin L, Hung S, Chi C, Tsai T. Analysis of silibinin in rat plasma and bile for hepatobiliary excretion and oral bioavailability application, Journal of Pharmaceutical and Biomedical Analysis, 2007; 45:635–641.
8. Tyler V, Phytomedicines in Western Europe: Their potential impact on herbal medicine in the United States, Herbalgram;1994;30:24–30
9. Decarli LM, Silymarin Retards the Progression of Alcohol-Induced Hepatic Fibrosis in Baboons, Journal of Clinical Gastroenterology, 2003; 37:336–339.
10. Zaulet M, Elvira S, Kevorkian M, Dinescu S, Cotoraci C, Suciu M, Protective effects of silymarin against bisphenol A-induced hepatotoxicity in mouse liver, Experimental and Therapeutic Medicine, 2017; 13:821–828.
11. Jiang K, Wang W, Jin X, Wang Z, Ji Z, Meng G, Silibinin , a natural flavonoid , induces autophagy via ROS-dependent mitochondrial dysfunction and loss of ATP involving BNIP3 in human MCF7 breast cancer cells, Oncology, 2015; 33:2711–2718.
12. Elmira S, Rouholamini Y, Moghassemi S, Maharat Z, Hakamivala A, Effect of silibinin-loaded nano-niosomal coated with trimethyl chitosan on miRNAs expression in 2D and 3D models of T47D breast cancer cell line, Artificial cells, Nanomedicine and Biotechnology, 2017; 1401:1–13.
13. Wu K, Zeng JIN, Li LEI, Fan J, Zhang D, Xue YAN, Silibinin reverses epithelial-to-mesenchymal transition in metastatic prostate cancer cells by targeting transcription factors, Oncology Reports, 2010; 23:1545–1552.
14. Tyagi A, Agarwal C, Harrison G, Glode LM, Agarwal R, Silibinin causes cell cycle arrest and apoptosis in human bladder transitional cell carcinoma cells by regulating CDKI-CDK-cyclin cascade, and caspase 3 and PARP cleavages, Carcinogenesis, 2004; 25(9):1711–1720.
15. Garg R, Gupta G Das, Preparation and evaluation of gastroretentive floating tablets of Silymarin, Chemical and Pharmaceutical Bulletin, 2009; 57(6):545–549.
16. Lu C, Lu Y, Chen J, Zhang W, Wu W,Synchronized and sustained release of multiple components in silymarin from erodible glyceryl monostearate matrix system, European Journal of Pharmaceutics and Biopharmaceutics, 2007; 66(2):210–219.
17. Nakhat P. D ,Naidu R. A, Babla I. B, Khan S and Yeole P. G, Design and evaluation of silymarin-HP- ? -CD solid dispersion tablets, Indian Journal of Pharmaceutical Sciences, 2007; 69(2):1–12.
18. Xie Y, Lu Y, Qi J, Li X, Zhang X, Han J, Synchronized and controlled release of multiple components in silymarin achieved by the osmotic release strategy, International Journal of Pharmaceutics, 2013; 441(1–2):111–20.
19. B Mohan, S Saini, NS Gill, Formulation and Evaluation of Fast Dissolving Tablet of Silymarin, PharmaTutor, 2014; 2(9):81-90.
20. Zeng QP, Liu ZH, Huang AW, Zhang J, Song HT, Preparation and characterization of silymarin synchronized-release microporous osmotic pump tablets, Drug Design Development Therapy, 2016; 10:519–531.
21. Ibrahim AH, Rosqvist E, Smatt J, Ibrahim HM, Ismael HR, Afouna MI, Formulation and optimization of lyophilized nanosuspension tablets to improve the physicochemical properties and provide immediate release of silymarin, International Journal of Pharmaceutics, 2019; 563(2):217–227.
22. Maheshwari H, Agarwal R, Patil C, Katare OP, Preparation and pharmacological evaluation of silibinin liposomes, Arzneimittel-Forschung/Drug Research, 2003; 53(6):420–427.
23. El-Samaligy MS, Afifi NN, Mahmoud EA, Evaluation of hybrid liposomes-encapsulated silymarin regarding physical stability and in vivo performance, International Journal of Pharmaceutics, 2006; 319(1–2):121–9.
24. Dube D, Khatri K, Goyal AK, Mishra N, Vyas SP, Preparation and evaluation of galactosylated vesicular carrier for hepatic targeting of silibinin, Drug Development and Industrial Pharmacy, 2010; 36(5):547–555.
25. Nitesh Q, Rai A, Reddy ND, Raj PV, Jain P, Deshpande P, Silymarin liposomes improves oral bioavailability of silybin besides targeting hepatocytes , and immune cells, Pharmacological Reports, 2014; 116:1–11.
26. Yang G, Zhao Y, Feng N, Zhang Y, Improved dissolution and bioavailability of silymarin delivered by a solid dispersion prepared using supercritical fluids, Asian Journal of Pharmaceutical Science, 2015; 1–9.
27. Wang M, Xie T, Chang Z, Wang L, Xie X, Kou Y, A New Type of Liquid Silymarin Proliposome Containing Bile Salts : Its Preparation and Improved Hepatoprotective Effects, Plos One, 2015; (1):1–15.
28. Yan-yu X, Yun-mei S, Zhi-peng C, Qi-neng P, Preparation of silymarin proliposome: A new way to increase oral bioavailability of silymarin in beagle dogs, International Journal of Pharmaceutics, 2006; 319(1–2):162–168.
29. Chu C, Tong S, Xu Y, Wang L, Fu M, Ge Y, Proliposomes for oral delivery of dehydrosilymarin : preparation and evaluation in vitro and in vivo, Nature Publishing Group, 2011; 32:973–980.
30. Mohamed MA, Hasanein AM, A SAA, Improved hepatoprotective activity of Silymarin via encapsulation in the novel vesicular nanosystem bilosomes, Drug Development and Industrial Pharmacy, 2017; 1–32.
31. Guo XH, Luo SN, Wang HY, Zhou L, Xie MH, Ye WZ, Study on the preparation and biodistribution of 99mTc-HMIBP, Nuclear Science Techniques, 2006; 17(5):285–288.
32. Shangguan M, Qi J, Lu Y, Wu W, Comparison of the oral bioavailability of silymarin-loaded lipid nanoparticles with their artificial lipolysate counterparts: implications on the contribution of integral structure, International Journal of Pharmaceutics, 2015; 489:195–202.
33. He J, Hou S, Lu W, Zhu L, Feng J, Preparation, Pharmacokinetics and Body Distribution of Silymarin-Loaded Solid Lipid Nanoparticles After Oral Administration, Journal of Biomedical Nanotechnology, 2007; 3(2):195–202.
34. He J, Hou S, Feng J, Cai B, Effect of particle size on oral absorption of silymarin- loaded solid lipid nanoparticles, China journal of Chinese material medica, 2005; 30(21):1651-1653.
35. Li FQ, Hu JH, Wang H, Zhu QG, Sun HJ, Cai Z, Relativities between lattice changes and the function of dissolution improvement of poorly soluble drug silymarin based upon PEG 6,000 solid dispersion system, Yao Xue Xue Bao, 2002; 37:294–298
36. Li FQ, Hu JH, Improvement of the dissolution rate of silymarin by means of solid dispersions, Chemical and Pharmaceutical Bulletin, 2004; 52(8):972–973.
37. Dalwadi S, Soni T, Thakkar V, Gandhi T, Silymarin-solid dispersions: Characterization and influence of preparation methods on dissolution, Acta Pharma, 2010; 60(4):427–443.
38. Sun N, Wei X, Wu B, Chen J, Lu Y & Wu W, Enhanced dissolution of silymarin / polyvinylpyrrolidone solid dispersion pellets prepared by a one-step fluid-bed coating technique, Powder Technology, 2008; 182:72–80.
39. Sun N, Zhang X, Lu Y, Wu W, In Vitro Evaluation and Pharmacokinetics in Dogs of Solid Dispersion Pellets Containing Silybum marianum extract prepared by Fluid-Bed Coating, Planta Medica. 2008; 74:126–132.
40. Yang G, Zhao Y, Feng N, & Zhang Y, Improved dissolution and bioavailability of silymarin delivered by a solid dispersion prepared using supercritical fluids. Asian Journal of Pharmaceutical Sciences. 2015; 10(3):1–9.
41. Sonali D, Tejal S, Vaishali T, Tejal G. Silymarin-solid dispersions: characterization and inﬂuence of preparation methods on dissolution. Acta Pharm. 2010; 60:427–443
42. Shin Y, Bae O, Yousaf AM, Yong CS, Kim JO & Choi H, A novel solid dispersion system for natural product-loaded medicine: silymarin-loaded solid dispersion with enhanced oral bioavailability and hepatoprotective activity, Journal of Microencapsulation, 2014; 2048:1–8.
43. Piacentini E, Pharmaceutical Particles Design by Membrane Emulsification: Preparation Methods and Applications in Drug Delivery, Current Pharmaceutical Design, 2018; 23(2):302–318.
44. Parveen R, Baboota S, Ali J, Ahuja A, Vasudev SS & Ahmad S, Effects of Silymarin Nanoemulsion against Carbon Tetrachloride- induced Hepatic Damage, Archieves of Pharmacal Research, 2011; 34(5):767–774.
45. Parveen R, Baboota S, Ali J, Ahuja A, Vasudev SS & Ahmad S, Oil based nanocarrier for improved oral delivery of silymarin: In vitro and in vivo studies, International Journal of Pharmaceutics, 2011; 413(1–2):245–253.
46. Parveen R, Baboota S, Ali J, Ahuja A & Ahmad S, Stability studies of silymarin nanoemulsion containing Tween 80 as a surfactant, Journal of Pharmacy and Bioallied Sciences, 2015; 7(4):321–324.
47. Ahmad U, Akhtar J, Singh SP, Badruddeen B, Ahmad FJ, Siddiqui S & Wahajuddin W, Silymarin nanoemulsion against human hepatocellular carcinoma: development and optimization, Artificial Cells, Nanomedicine and Biotechnology, 2018; 46(2): 231–241.
48. Piazzini V, Rosseti C, Bigagli E & Bergonzi MC, Prediction of Permeation and Cellular Transport of Silybum marianum Extract Formulated in a Nanoemulsion by Using PAMPA and Caco-2 Cell Models, Planta Medica, 2017; 83:1184–1193.
49. Nagi A, Iqbal B, Kumar S, Sharma S, Ali J, Baboota S, Quality by design based silymarin nanoemulsion for enhancement of oral bioavailability, Journal of Drug Delivery Science and Technology, 2017; 40:35-44.
50. Shih T & Yeh T, Self-nanoemulsifying drug delivery systems ameliorate the oral delivery of silymarin in rats with Roux-en-Y gastric bypass surgery, International Journal of Nanomedicine, 2015; 10:2403–2416.
51. Woo JS, Kim T, Park J & Chi S, Formulation and Biopharmaceutical Evaluation of Silymarin Using SMEDDS, Plos One, 2007;30(1):82–89.
52. Abrol S, Trehan A, Katare OP, Formulation, characterization, and in vitro evaluation of silymarin-loaded lipid microspheres, Drug Delivery, 2004; 11:185–191
53. Abrol S, Trehan A, Katare OP, Comparative study of different silymarin formulations: formulation, characterisation and in vitro/in vivo evaluation, Current Drug Delivery, 2005; 2:45–51
54. Zhu Y, Wang M, Zhang Y, Zeng J, Yu J, & Xu X, In Vitro Release and Bioavailability of Silybin from Micelle-Templated Porous Calcium Phosphate Microparticles, APPS Pharma Sci Tech, 2015; 17(5): 1–8.
55. Garg R, Gupta GD, Preparation and evaluation of gastroretentive ﬂoating tablets of silymarin, Chemical and Pharmaceutical Bulletin, 2009; 57(6):545–549.
56. Chaudhary S, Garg T, Murthy RSR, Rath G and Goyal AK, Development, optimization and evaluation of long chain nanolipid carrier for hepatic delivery of silymarin through lymphatic transport pathway, International Journal of Pharmaceutics, 2015; 14706:1-14
57. Piazzini V, Lemmi B, Ambrosio MD, Cinci L, Luceri C, Bilia AR, & Bergonzi MC, Nanostructured Lipid Carriers as Promising Delivery Systems for Plant Extracts: The Case of Silymarin, Applied Sciences, 2018; 1163(8):1-15.
58. Shangguan M, Lu Y, Qi J, Han J, Tian Z, Xie Y, Wu W, Binary lipids-based nanostructured lipid carriers for improved oral bioavailability of silymarin, Journal of Biomaterials Applications, 2014; 28(6):887–896.
59. Piazzini V, Ambrosio MD, Luceri C, Cinci L, Landucci E, Bilia AR, & Bergonzi MC, Formulation of Nanomicelles to Improve the Solubility and the Oral Absorption of Silymarin, Molecules, 2019; 24:1–20.
60. Onodera R, Hayashi T, Nakamura T, Aibe K, Tahara K, & Takeuchi H, Preparation of silymarin nanocrystals using a novel high-pressure crystallization technique and evaluation of its dissolution and absorption. Asian Journal of Pharmaceutical Sciences, 2016; 11(1):211–212.
61. El-batal AI, Elmenshawi SF, Ali AMA, & Goodha E. Preparation and Characterization of Silymarin Nanocrystals and Phytosomes with Investigation of their Stability using Gamma Irradiation, Indian Journal of Pharmaceutical Education and Research, 2018; 52(4):174-183.
62. El-Nahas AE, Allam AN, & El-Kamel A H, Mucoadhesive buccal tablets containing silymarin Eudragit-loaded nanoparticles: formulation, characterisation and ex vivo permeation, Journal of Microencapsulation, 2017; 34(5):463–474.
63. Cao X, Fu M, Wang L, Liu H, Deng W, Qu R, Oral bioavailability of silymarin formulated as a novel 3-day delivery system based on porous silica nanoparticles, Acta Biomater, 2012; 8(6):2104–2112.
64. Wu W, Zu Y, Wang L, Li Y, & Liu Y, Preparation, characterization and antitumor activity evaluation of silibinin nanoparticles for oral delivery through liquid antisolvent precipitation, RSC Advances, 2017; 7:54379–54390.
65. Bae O and Kim JO, Silymarin-loaded solid nanoparticles provide excellent hepatic protection: physicochemical characterization and in vivo evaluation, International Journal of Nanomedicine, 2013; 8:3333–3343.
66. Deng Y, Zhang Y, Zu Y, Bolin L, Wu M, Wu W, Silymarin nanoparticles through emulsion solvent evaporation method for oral delivery with high antioxidant activities, bioavailability, and absorption in the liver, RSC Advances, 2016;1-12.
67. Arcari M , Brambilla A, Brandt A, Caponi R, Corsi G, Rella M, Solinas F, Wachter W P, A new inclusion complex of silibinin and beta-cyclodextrins: in vitro dissolution kinetics and in vivo absorption in comparison with traditional formulations, Bollettino Chimico Farmaceutico, 1992; 131(5):205-209.
68. Ghosh A, Biswas S, Ghosh T, Preparation and evaluation of silymarin b-cyclodextrin molecular inclusion complexes, Journal of Young Pharmacists, 2011; 3:205–210.
69. Javed S, Kohil K, & Ahsan W, Solubility and Dissolution Enhancement of Silymarin with Fulvic Acid, International Journal of Drug Development and Research, 2016; 8(1):9–14.
70. Shetty PK, Manikkath J, Tupally K, Kokil G, Hegde AR, Raut SY, Mutalik S, Skin Delivery of EGCG and Silibinin: Potential of Peptide Dendrimers for Enhanced Skin Permeation and Deposition, AAPS PharmSciTech, 2017; 18(6):2346–2357.
71. Vidal F, Pilar V, Cayum F R, Carola D, Fuentealba J, Aguayo LG ,Guzm L, Prevention of Synaptic Alterations and Neurotoxic Effects of PAMAM Dendrimers by Surface Functionalization, Nanomaterials, 2007; 8(1):1-12.
72. Mady FM, Essa H, El-Ammawi T, Abdelkader H & Hussein AK. Formulation and clinical evaluation of silymarin pluronic-lecithin organogels for treatment of atopic dermatitis, Drug Design, Development and Therapy, 2016;10:1101–1110
73. Zohreh F, Amir G, Masoud G, In-vitro and In-vivo Evaluation of Silymarin Nanoliposomes against Isolated Methicillin-resistant Staphylococcus aureus, Iranian Journal of Pharmaceutical Research, 2015; 14(2):627-633.
74. Netto G, Jobin J, Development, characterization, and evaluation of sunscreen cream containing solid lipid nanoparticles of silymarin, Journal of Cosmetic Dermatology, 2017; 17(6):1073-1083.
75. Praphanwittaya P, Chomto P, & Phaechamud T, Silymarin Solid Lipid Nanoparticle containing Shellac Wax Fabricated with Hot Melt Emulsification, Journal of Pharmaceutical, Biological and Chemical Sciences, 2013; 4(1):784-801
76. Panapisal V, Charoensri S & Tantituvanont A, Formulation of microemulsion systems for dermal delivery of silymarin, AAPS PharmSciTech, 2012; 13(2):389–399.
77. Singh P, Arya M, Kanoujia J, Singh M, Gupta KP & Saraf SA, Design of topical nanostructured lipid carrier of silymarin and its effect on 7,12-dimethylbenz[a] anthracene (DMBA) induced cellular differentiation in mouse skin, RSC Advances, 2016; 6(88):84965–84977.
78. Singh P, Singh M, Kanoujia J & Arya M, Process optimization and photostability of silymarin nanostructured lipid carriers : effect on UV-irradiated rat skin and SK-MEL 2 cell line, Drug Delivery and Translational Research, 2016; 6:597-609.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).